Insight
The validated evidence sits in MPS II, not in Alzheimer's
Transferrin receptor shuttles are the only blood-brain barrier delivery class with an approval behind them. Both of the approvals that hold up to a primary record treat the same lysosomal storage disease, and the transfer of that result to neurodegeneration has not been made.
What is actually approved
Tividenofusp alfa was granted accelerated approval in the United States in March 2026 for mucopolysaccharidosis type II (MPS II). Its label names the apical domain of the transferrin receptor as the route across the barrier.
AVLAYAH US Prescribing Information, revised 3/2026, Reference ID 5769209, section 12.1.
Pabinafusp alfa was approved in Japan in March 2021, also for MPS II. Its mechanism is confirmed from a peer-reviewed paper written by employees of the sponsor: a fusion of human iduronate-2-sulfatase with a humanised anti-human transferrin receptor antibody.
Yamamoto R, Kawashima S. Nihon Yakurigaku Zasshi 2022;157(1):62-75. doi:10.1254/fpj.21080.
A third asset, verenafusp alfa, is reported approved in Russia for the same indication. That approval was not verified against a regulator record in this pass and is carried at LOW confidence. It is listed here because striking it silently would be the error this practice is set up to avoid.
ClinicalTrials.gov NCT06475404, Phase 1 in healthy volunteers, sponsor AO GENERIUM. Approval reported in secondary coverage only.
What the approval was granted on
The tividenofusp alfa accelerated approval rests on cerebrospinal fluid heparan sulfate, a surrogate. In the Phase 1/2 population of 47, cerebrospinal fluid heparan sulfate fell by 91% at Week 24 (95% CI 89%, 92%), and 41 of 44 evaluable participants were below the upper limit of normal.
AVLAYAH US Prescribing Information, revised 3/2026, Reference ID 5769209. Trial 1 is ClinicalTrials.gov NCT04251026. Phase 1/2 results published as N Engl J Med 2026;394:39-50, doi:10.1056/NEJMoa2508681.
That is a strong result for what it is. It establishes that a large enzyme conjugated to a transferrin receptor binder reaches the central nervous system in humans at a dose that moves a disease-relevant substrate. It does not establish that the substrate reduction produces a clinical benefit, which is what accelerated approval defers by design.
Why MPS II is an unusually favourable case
MPS II is monogenic, with a single deficient enzyme and a substrate that accumulates measurably in cerebrospinal fluid. The pharmacodynamic question and the delivery question are answered by the same assay. Replace the missing enzyme in the right compartment and the substrate falls.
Alzheimer's disease offers neither of those conveniences. There is no monogenic defect in the sporadic population, the target engagement readout is amyloid clearance on positron emission tomography rather than correction of a deficiency, and the link from that readout to a clinical outcome is the contested part of the field rather than the settled part.
The asset carrying the transfer
Trontinemab is the programme on which the transfer from lysosomal disease to neurodegeneration currently rests. Roche describe it as a Brainshuttle bispecific 2+1 amyloid-beta antibody, and the transferrin receptor attribution comes from a Roche publication and a Roche press release read together rather than from either alone.
Niewoehner et al., Neuron 2014; Roche press release, 7 July 2026; Kulic et al., AAIC 2026, slide 4.
Three Phase 3 studies are registered. TRONTIER 1 and TRONTIER 2 take change from baseline to Week 72 in the Clinical Dementia Rating, Sum of Boxes as their primary outcome. PrevenTRON takes time to progression in cognitively unimpaired individuals. None has reported.
ClinicalTrials.gov NCT07169578, NCT07170150 and NCT07717411.
The amyloid removal is not in dispute. In the open-label extension, 54 of 59 participants at 3.6 mg/kg were below 24 centiloids at Day 196, and 42 of 59 were below 11 centiloids. What is undisclosed is any clinical readout at all.
Kulic et al., AAIC 2026, slide 7. Parts 1 and 2, snapshot 31 October 2025.
The prior on the target mechanism
Pooling eight Phase 3 datasets, the effect of anti-amyloid antibodies on the Clinical Dementia Rating, Sum of Boxes is -0.33 points (95% credible interval -0.54 to -0.10), which sits below the minimal clinically important difference for mild cognitive impairment and mild Alzheimer's disease. The predicted effect for a further study with a similar antibody spans -0.88 to +0.25, so a null result remains inside the expected range.
Teipel SJ, Temp AGM, Lutz MW. Alzheimers Dement (N Y) 2024;10(1):e12454. doi:10.1002/trc2.12454.
Better delivery raises the exposure. It does not change what the target does once the antibody arrives. Those are two questions and the field's validated evidence currently answers only the first one, in a disease that is not neurodegeneration.
What this piece is not claiming
No position is taken on whether trontinemab will read out positively. The pooled estimate above covers antibodies at conventional brain exposures, and whether a several-fold increase in exposure moves the result is precisely what the Phase 3 programme is being run to find out.
The narrower point stands on its own. When a delivery platform is described as clinically validated, it is worth asking which disease validated it, on what endpoint, and whether that endpoint was clinical or a surrogate.